cGAS-STING pathway expression as a prognostic tool in NSCLC.

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Lung adenocarcinoma recurrence poses a significant challenge to patient outcomes.
• Identifying prognostic biomarkers is crucial for risk stratification.
• Immune detection of tumor cells, involving DNA sensing via the cGAS-STING pathway, is vital for cancer clearance.

Purpose of the Study:

• To investigate the expression of the cGAS-STING pathway in tumor tissue and circulating immune cells of lung adenocarcinoma patients.
• To correlate cGAS-STING pathway expression with disease stage and overall survival (OS).

Main Methods:

• Gene expression analysis using droplet digital polymerase chain reaction (ddPCR) in 80 lung adenocarcinoma patients and 45 cancer-free individuals.
• Correlation of expression levels with disease stage.
• Utilizing publicly available gene expression datasets to analyze stage-dependent expression and its relation to OS.

Main Results:

• Differential expression of cGAS-STING pathway components was observed in tumor tissue and peripheral blood mononuclear cells (PBMCs) of cancer patients compared to controls.
• cGAS-STING pathway expression was higher in PBMCs of patients with localized disease (Stage I/II) versus metastatic disease (Stage III/IV).
• Survival analysis revealed superior OS in patients with localized disease and high expression of cGAS, STING, and TBK1.

Conclusions:

• cGAS-STING pathway expression is stage-dependent in lung adenocarcinoma.
• High expression of cGAS, STING, and TBK1 correlates with localized disease and improved OS.
• These genes may represent potential prognostic biomarkers for patients with localized lung adenocarcinoma.